For the quarter ended December 2025, Integer (ITGR) reported revenue of $472.06 million, up 5% over the same period last year. EPS came in at $1.76, compared to $1.43 in the year-ago quarter.
The reported revenue represents a surprise of +2.04% over the Zacks Consensus Estimate of $462.63 million. With the consensus EPS estimate being $1.70, the EPS surprise was +3.62%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Integer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales- Medical Sales- Other Markets: $20.55 million versus $16.59 million estimated by five analysts on average.
- Sales- Medical Sales- Cardio & Vascular: $284.21 million versus the five-analyst average estimate of $274.01 million. The reported number represents a year-over-year change of +11.3%.
- Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation: $167.3 million versus $172.57 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -1.9% change.
View all Key Company Metrics for Integer here>>>
Shares of Integer have returned -0.6% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Integer Holdings Corporation (ITGR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
